Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

RECRUITING
REcovery from DEXmedetomidine-induced Unconsciousness
Description

This pilot study in healthy volunteers aims to determine if biological sex has an impact on recovery from dexmedetomidine-induced unconsciousness, and if transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) can be used to measure brain complexity during dexmedetomidine sedation without arousing study participants.

COMPLETED
Race-Specific Propofol Titration to Effect for Procedural Sedation
Description

Prospectively evaluate newly established guidelines and make clinicians aware of inter-racial difference in propofol sensitivity.

COMPLETED
UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study
Description

This study will be a single-site, controlled, unblinded study at the University of Wisconsin to examine changes in the electroencephalogram during anesthesia and waking.

ACTIVE_NOT_RECRUITING
BAsel Syncope EvaLuation (BASEL IX) Study
Description

Syncope is a major health problem. In the emergency department (ED), the management of patients with syncope still remains a clinical challenge because underlying diseases and prognosis can be extremely various. Structural heart disease and primary electrical disorders are major risk factors for sudden cardiac death and mortality in patients with syncope. In contrast, patients with reflex syncope and exclusion of structural heart disease have an excellent prognosis. Therefore The investigators test the hypothesis that the use of a meticulous patient history, clinical examination and novel biomarkers can improve the rapid and accurate diagnosis of cardiac syncope in patients presenting to the ED and is able to improve risk stratification regarding adverse outcomes. The prospective multicenter cohort study is designed to enroll 720 patients presenting with transient loss of consciousness within the last 12 hours to the ED. Blood samples for the measurement of novel biomarkers will be obtained at presentation. All patients will be contacted by phone at 6, 12 and 24 months to determine major adverse events (death, resuscitation, recurrence of syncope, hospitalization for syncope).

Conditions